May contain inaccuracies · Check primary sources · Not medical advice · Not for human or animal use

Non-peptide

LGD-4033

Also known as

Ligandrol · VK5211 · VK-5211 · LGD · LGD4033 · LGD 4033 · Anabolicum · LGD4033 (Ligandrol)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

IdentityLigandrol, also called VK5211, is an experimental non-peptide SARM that activates androgen receptors. It is an unapproved drug.
Why people discuss itMuscle, strength and a fuller physique drive interest; selectivity does not establish freedom from side effects.
Notes

LGD-4033, also called Ligandrol or VK5211, is an experimental SARM discussed for muscle, strength and a fuller physique. Some logs describe better workouts; others report little change, low energy or sexual and laboratory changes. It is an unapproved drug, and a stronger lift does not prove new muscle or safety.

Ligandrol is a non-peptide SARM. It activates androgen receptors, the body's receivers for signals such as testosterone. Discussion involves capsules, tablets and liquids; it is a different compound from testosterone or LGD-3303. Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror) (Official context · Accessed 2026-09-30)

Selective does not mean side-effect free. The appeal is muscle and strength without injections. Community rankings call it stronger than Ostarine, but those comparisons cannot establish equal exposures, safety or a head-to-head winner.

Source context — Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror): Primary-paper mirror; short, low-dose, Ligand-funded study. No validation of recreational exposure. Direct PMC blocked; Europe PMC failed.

What people notice

Workouts and appearanceSome report stronger lifts, better pumps, less soreness and fuller muscles. Water can contribute to the changed look.
Little change also occursOne nearly eight-week user noticed little change; another longer log ended only 1 kg heavier as training changed.
Notes

Stronger lifts and fuller muscles. Reports describe better pumps, less soreness and faster lift progression. A fuller appearance can include water; the brief-log author explicitly questioned how much of his changed look was muscle. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30) · LGD 8+ week log (Community discussion · Accessed 2026-09-30)

Recomp depends on the rest of the picture. People discuss holding muscle while leaning out, yet food intake, extra training and stacks change the outcome. The longer log ended only 1 kg heavier after rowing increased; a nearly eight-week user noticed little change. LGD first cycle report (Personal report · Accessed 2026-09-30) · 8 week LGD4 failure? (Science.bio) (Community discussion · Accessed 2026-09-30)

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Source context — LGD 8+ week log: Anonymous unverified dose/product and surplus; no controlled body composition or post-stop outcome. Two users' trajectories remain separate.

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — 8 week LGD4 failure? (Science.bio): Anonymous accounts, unverified product, no author bloodwork. Seller participates commercially; its assurances/lab-report mention do not authenticate the consumed bottle. No-response dose belongs to OP, not other commenters.

Doses people talk about

Swallowed daily discussion2.5–5 mg/day and 5–10 mg/day are separate chart bands. Logs include 5 mg/day nonresponse and a 5-to-10 mg/day course; these are reported exposures.
Under-the-tongue accountOne person used 3 mg/day under the tongue for 11 days. Equivalent absorption or liver protection was not established.
Higher amountsA log reached 12–15 mg/day; outlier reports reach 20–30 mg/day. These exceed the short repeated-dose trial exposures.
Notes

Swallowed/oral talk: 2.5–5 and 5–10 mg/day. These separate lower and larger daily bands recur in community/vendor charts. Logs include a 2.5 mg morning account, a liquid 5 mg/day nonresponse and a 5-to-10 mg/day course; they are descriptions, not an escalation plan. How often you dose your LGD (Community discussion · Accessed 2026-09-30) · 8 week LGD4 failure? (Science.bio) (Community discussion · Accessed 2026-09-30) · LGD first cycle report (Personal report · Accessed 2026-09-30)

Sublingual: one 3 mg/day report. The author dissolved a tablet under the tongue each morning for 11 days. This route is distinct from swallowing; equivalent absorption and liver protection were not established. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30)

Higher and disputed amounts. A log reached 12–15 mg/day; outlier accounts reach 20–30 mg/day. An older forum reports 0.3–0.5 mg, but replies question units. Female guide bands of 1–5 mg/day are unvalidated chart talk, not studied female protocols. LGD 8+ week log (Community discussion · Accessed 2026-09-30) · All of your SARMS1 questions — page 23 (Community discussion · Accessed 2026-09-30)

The trial was a different exposure. Basaria studied 0.1, 0.3 or 1 mg orally over 21 days. Lean mass increased, but strength gains were not significant versus placebo. Testosterone and HDL fell; 24–36-hour half-life and accumulation were measured. Short-trial recovery does not establish recovery after larger community courses. Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror) (Official context · Accessed 2026-09-30)

Source context — How often you dose your LGD: A single perceived fade is not measured half-life, drug clearance or proof of an 18-hour redosing need. Morning testosterone rationale unsupported.

Source context — 8 week LGD4 failure? (Science.bio): Anonymous accounts, unverified product, no author bloodwork. Seller participates commercially; its assurances/lab-report mention do not authenticate the consumed bottle. No-response dose belongs to OP, not other commenters.

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Source context — LGD 8+ week log: Anonymous unverified dose/product and surplus; no controlled body composition or post-stop outcome. Two users' trajectories remain separate.

Source context — All of your SARMS1 questions — page 23: Sponsor-focused thread with commercial advice; daily frequency/form not independently clear. Reply questions units, so stated amounts retained as disputed account, not verified low-dose efficacy.

Source context — Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror): Primary-paper mirror; short, low-dose, Ligand-funded study. No validation of recreational exposure. Direct PMC blocked; Europe PMC failed.

Half-life, onset & duration

Felt onsetSome report better lifts within ten days to two weeks; another noticed little until week five. Some notice little even after weeks.
Felt durationOne person described fading at 18 hours, amount unstated. No dependable single-dose or post-stop benefit window follows from the logs.
Half-life24–36 hours comes from controlled human blood-level measurements, repeated in forums; it does not measure a pump or verify clearance of an unknown product.
Notes

Early changes versus week five. The brief user noticed better lifts within ten days; another commenter described a bench plateau breaking within two weeks. The longer-log author felt little strength difference until week five, then more PRs in weeks seven to nine. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30) · LGD Average cycle results? (Community discussion · Accessed 2026-09-30) · LGD first cycle report (Personal report · Accessed 2026-09-30)

Some notice little even after weeks. The nearly eight-week liquid account reported no major strength or pump change. No dependable minute-by-minute onset after a dose emerges from these logs. 8 week LGD4 failure? (Science.bio) (Community discussion · Accessed 2026-09-30)

An 18-hour fade is one subjective account. A timing-thread commenter felt effects disappearing then, without naming an amount. That is not a measured one-dose benefit window or a reason to copy the schedule. How often you dose your LGD (Community discussion · Accessed 2026-09-30)

Post-stop strength and weight vary. One author reported PRs during the first week after stopping. The eight-week bench commenter retained much of the gained weight but gave no follow-up interval. Neither establishes permanent muscle retention or normal hormone recovery. LGD first cycle report (Personal report · Accessed 2026-09-30) · LGD Average cycle results? (Community discussion · Accessed 2026-09-30)

24–36 hours is a circulated study figure. Forum users repeat it and disagree over 24 versus 36 hours. Its origin is controlled human pharmacokinetics, not their own measurements; it cannot tell someone how long a pump lasts or when a gray-market product clears. LGD-4033 half life and how to structure dosing (Secondhand community claim · Accessed 2026-09-30) · How often you dose your LGD (Community discussion · Accessed 2026-09-30)

The trial was a different exposure. Basaria studied 0.1, 0.3 or 1 mg orally over 21 days. Lean mass increased, but strength gains were not significant versus placebo. Testosterone and HDL fell; 24–36-hour half-life and accumulation were measured. Short-trial recovery does not establish recovery after larger community courses. Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror) (Official context · Accessed 2026-09-30)

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Source context — LGD Average cycle results?: Anonymous deleted contributor; follow-up interval, form and product authenticity unknown. Strength and scale changes do not measure isolated new muscle.

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — 8 week LGD4 failure? (Science.bio): Anonymous accounts, unverified product, no author bloodwork. Seller participates commercially; its assurances/lab-report mention do not authenticate the consumed bottle. No-response dose belongs to OP, not other commenters.

Source context — How often you dose your LGD: A single perceived fade is not measured half-life, drug clearance or proof of an 18-hour redosing need. Morning testosterone rationale unsupported.

Source context — LGD-4033 half life and how to structure dosing: Forum repetition, not user-measured human pharmacokinetics. Replies asserting doses already ensure safety lack validation.

Source context — Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror): Primary-paper mirror; short, low-dose, Ligand-funded study. No validation of recreational exposure. Direct PMC blocked; Europe PMC failed.

Cycles people discuss

Blocks discussedSix-to-eight-week blocks recur; four-week runs and eight-to-twelve-week extensions also appear. Some users stop much earlier.
Post-cycle treatment and time offTamoxifen or clomiphene after a run, and bloodwork, are discussed. Time-off-equals-time-on is a forum rule of thumb, not a validated recovery schedule.
Notes

Six to eight weeks; longer runs also occur. Community charts include four-week exploratory runs, six-to-eight-week blocks and eight-to-twelve-week extensions. Reports include an 11-day stop, an interrupted ten-calendar-week course and an eight-week bench log whose gains slowed at the end. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30) · LGD first cycle report (Personal report · Accessed 2026-09-30) · LGD Average cycle results? (Community discussion · Accessed 2026-09-30)

PCT and time off are contested. Forums discuss post-cycle SERMs such as tamoxifen or clomiphene, sometimes on-cycle use, and bloodwork before/during/after. The 'time off at least equals time on' heuristic and multi-week recovery stories are not validated LGD recovery schedules. LGD first cycle report (Personal report · Accessed 2026-09-30)

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — LGD Average cycle results?: Anonymous deleted contributor; follow-up interval, form and product authenticity unknown. Strength and scale changes do not measure isolated new muscle.

Stacks

MK-677 and other agentsMK-677 appears for appetite and recovery; RAD-140, Ostarine, S-4, YK-11 and cardarine occur in other combinations. Results cannot be assigned to LGD alone.
Support supplementsFish oil and liver-support products appear, but adding them does not establish protection from harm.
Notes

Stack gains cannot be assigned to LGD alone. MK-677 appears for appetite/recovery; RAD-140, Ostarine, S-4, YK-11 and GW-501516 occur in other stack talk. The longer author added MK-677 alongside injury care. Adding agents obscures benefit and adverse-effect attribution. LGD first cycle report (Personal report · Accessed 2026-09-30)

Support supplements are not a shield. Fish oil and liver-support products appear in stack discussions alongside warnings about heavy alcohol and other liver-stressing orals. Adding 'support' does not establish protection; the brief adverse log included multiple such products. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30)

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Watch for

Hormones, liver and lipidsReports include falling testosterone, low libido, fatigue and elevated liver enzymes. The short trial also found testosterone and HDL reductions.
Other unwanted effectsNausea, abdominal discomfort, night sweats, headaches, flat mood, acne and shedding appear; female masculinization risk remains uncertain.
Serious class risksFDA identifies liver injury, sexual dysfunction, infertility and cardiovascular risks with SARMs. Feeling stronger does not establish safety.
Sport and product identityLigandrol is prohibited in sport at all times in the saved WADA record. Neither a pump nor nonresponse authenticates a bottle.
Notes

Better workouts can coexist with feeling worse. The brief user stopped with nausea, abdominal discomfort, night sweats, dehydration, flat mood and reduced aerobic capacity. His liver enzymes rose and testosterone fell; other medicines make causality uncertain. Higher-dose logs include fatigue, headaches and low libido. My (brief) experience with LGD-4033 (3mg) (Personal report · Accessed 2026-09-30) · LGD 8+ week log (Community discussion · Accessed 2026-09-30)

Feeling fine does not prove no suppression. The nonresponder had no bloodwork. The longer author described libido rising around weeks three to four then falling, despite feeling leaner and stronger. That author reported substantial hormone suppression; a separate user described sluggish mood. 8 week LGD4 failure? (Science.bio) (Community discussion · Accessed 2026-09-30) · LGD first cycle report (Personal report · Accessed 2026-09-30)

The trial was a different exposure. Basaria studied 0.1, 0.3 or 1 mg orally over 21 days. Lean mass increased, but strength gains were not significant versus placebo. Testosterone and HDL fell; 24–36-hour half-life and accumulation were measured. Short-trial recovery does not establish recovery after larger community courses. Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror) (Official context · Accessed 2026-09-30)

Skin, hair and female risks remain uncertain. Reports include acne, shedding and variable mood. Masculinization concerns accompany female chart talk; lower amounts do not establish protection against voice or other androgen-related changes.

Unapproved drug and serious class risks. FDA identifies liver injury, sexual dysfunction, infertility and cardiovascular risks with SARMs. 'Research use only' marketing does not establish safety or make them approved dietary supplements. FDA warning on SARMs among teens and young adults (Official context · Accessed 2026-09-30)

LGD-4033, also called Ligandrol or VK5211, is an experimental SARM discussed for muscle, strength and a fuller physique. Some logs describe better workouts; others report little change, low energy or sexual and laboratory changes. It is an unapproved drug, and a stronger lift does not prove new muscle or safety.

Prohibited in sport at all times. WADA's 2026 list names Ligandrol. A half-life estimate does not provide an anti-doping clearance day. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)

More milligrams do not settle nonresponse. Comments argue weak response versus incorrect product identity. Capsules, tablets and liquids bring different counting/error questions, and seller assurances cannot identify a consumed bottle. Neither no response nor a dramatic pump proves authenticity. 8 week LGD4 failure? (Science.bio) (Community discussion · Accessed 2026-09-30)

Source context — My (brief) experience with LGD-4033 (3mg): Anonymous self-report and unverified product. DHEA, tirzepatide, telmisartan and multiple supplements confound attribution. Relative date only; no exact publication date inferred. Sublingual liver-protection claim is unsupported.

Source context — LGD 8+ week log: Anonymous unverified dose/product and surplus; no controlled body composition or post-stop outcome. Two users' trajectories remain separate.

Source context — 8 week LGD4 failure? (Science.bio): Anonymous accounts, unverified product, no author bloodwork. Seller participates commercially; its assurances/lab-report mention do not authenticate the consumed bottle. No-response dose belongs to OP, not other commenters.

Source context — LGD first cycle report: Anonymous, unverified product; oral form not specified in post. Diet/training changes, travel interruptions, injury care and MK-677 confound results. Exact date not independently extracted.

Source context — Basaria et al. — LGD-4033 in healthy men (primary paper, PDF mirror): Primary-paper mirror; short, low-dose, Ligand-funded study. No validation of recreational exposure. Direct PMC blocked; Europe PMC failed.

Source context — FDA warning on SARMs among teens and young adults: Class warning, not LGD-specific incidence or proof of causation in any particular forum report. Exact page publication date not inferred.

Source context — WADA 2026 Prohibited List: Sport rule only, no biological clearance or detection window supplied.

Full notes

LGD-4033, also called Ligandrol or VK5211, is an experimental SARM discussed for muscle, strength and a fuller physique. Some logs describe better workouts; others report little change, low energy or sexual and laboratory changes. It is an unapproved drug, and a stronger lift does not prove new muscle or safety.

What LGD-4033 is

  • Ligandrol is a non-peptide SARM. It activates androgen receptors, the body's receivers for signals such as testosterone. Discussion involves capsules, tablets and liquids; it is a different compound from testosterone or LGD-3303. Official context Community Community
  • Selective does not mean side-effect free. The appeal is muscle and strength without injections. Community rankings call it stronger than Ostarine, but those comparisons cannot establish equal exposures, safety or a head-to-head winner. Community

What people hope to get

  • Stronger lifts and fuller muscles. Reports describe better pumps, less soreness and faster lift progression. A fuller appearance can include water; the brief-log author explicitly questioned how much of his changed look was muscle. Personal report Reddit r/sarmssourcetalk
  • Recomp depends on the rest of the picture. People discuss holding muscle while leaning out, yet food intake, extra training and stacks change the outcome. The longer log ended only 1 kg heavier after rowing increased; a nearly eight-week user noticed little change. Personal report Reddit r/sarmssourcetalk Community

Doses people discuss

  • Swallowed/oral talk: 2.5–5 and 5–10 mg/day. These separate lower and larger daily bands recur in community/vendor charts. Logs include a 2.5 mg morning account, a liquid 5 mg/day nonresponse and a 5-to-10 mg/day course; they are descriptions, not an escalation plan. Community Reddit r/sarmssourcetalk Reddit r/sarmssourcetalk Personal report
  • Sublingual: one 3 mg/day report. The author dissolved a tablet under the tongue each morning for 11 days. This route is distinct from swallowing; equivalent absorption and liver protection were not established. Personal report
  • Higher and disputed amounts. A log reached 12–15 mg/day; outlier accounts reach 20–30 mg/day. An older forum reports 0.3–0.5 mg, but replies question units. Female guide bands of 1–5 mg/day are unvalidated chart talk, not studied female protocols. Reddit r/sarmssourcetalk Community EliteFitness

Half-life in community discussion

  • 24–36 hours is a circulated study figure. Forum users repeat it and disagree over 24 versus 36 hours. Its origin is controlled human pharmacokinetics, not their own measurements; it cannot tell someone how long a pump lasts or when a gray-market product clears. Reddit r/SARMs Reddit r/sarmssourcetalk
  • Once daily is discussed; schedule arguments remain. Morning, afternoon, split and longer intervals appear. Accumulation talk does not validate pre-workout concentration arithmetic, indefinite buildup claims or a personally safe interval. Reddit r/sarmssourcetalk AnabolicMinds

When people notice changes

  • Early changes versus week five. The brief user noticed better lifts within ten days; another commenter described a bench plateau breaking within two weeks. The longer-log author felt little strength difference until week five, then more PRs in weeks seven to nine. Personal report Reddit r/sarmssourcetalk Personal report
  • Some notice little even after weeks. The nearly eight-week liquid account reported no major strength or pump change. No dependable minute-by-minute onset after a dose emerges from these logs. Reddit r/sarmssourcetalk

How long reported effects last

  • An 18-hour fade is one subjective account. A timing-thread commenter felt effects disappearing then, without naming an amount. That is not a measured one-dose benefit window or a reason to copy the schedule. Reddit r/sarmssourcetalk
  • Post-stop strength and weight vary. One author reported PRs during the first week after stopping. The eight-week bench commenter retained much of the gained weight but gave no follow-up interval. Neither establishes permanent muscle retention or normal hormone recovery. Personal report Reddit r/sarmssourcetalk

Courses and breaks people describe

  • Six to eight weeks; longer runs also occur. Community charts include four-week exploratory runs, six-to-eight-week blocks and eight-to-twelve-week extensions. Reports include an 11-day stop, an interrupted ten-calendar-week course and an eight-week bench log whose gains slowed at the end. Community Personal report Personal report Reddit r/sarmssourcetalk
  • PCT and time off are contested. Forums discuss post-cycle SERMs such as tamoxifen or clomiphene, sometimes on-cycle use, and bloodwork before/during/after. The 'time off at least equals time on' heuristic and multi-week recovery stories are not validated LGD recovery schedules. Community Personal report

What can change the decision

  • Better workouts can coexist with feeling worse. The brief user stopped with nausea, abdominal discomfort, night sweats, dehydration, flat mood and reduced aerobic capacity. His liver enzymes rose and testosterone fell; other medicines make causality uncertain. Higher-dose logs include fatigue, headaches and low libido. Personal report Reddit r/sarmssourcetalk
  • Skin, hair and female risks remain uncertain. Reports include acne, shedding and variable mood. Masculinization concerns accompany female chart talk; lower amounts do not establish protection against voice or other androgen-related changes. Community Community
  • Unapproved drug and serious class risks. FDA identifies liver injury, sexual dysfunction, infertility and cardiovascular risks with SARMs. 'Research use only' marketing does not establish safety or make them approved dietary supplements. Official context
  • Prohibited in sport at all times. WADA's 2026 list names Ligandrol. A half-life estimate does not provide an anti-doping clearance day. Official context

Supporting human research

  • The trial was a different exposure. Basaria studied 0.1, 0.3 or 1 mg orally over 21 days. Lean mass increased, but strength gains were not significant versus placebo. Testosterone and HDL fell; 24–36-hour half-life and accumulation were measured. Short-trial recovery does not establish recovery after larger community courses. Official context

What the logs add

  • A stronger bench is not a measured muscle gain. One 5 mg/day commenter reported bench rising from 335 to 360 lb and about six pounds gained over eight weeks with a slight surplus. Water contribution was uncertain, and progress slowed rather than improving indefinitely. Reddit r/sarmssourcetalk
  • Feeling fine does not prove no suppression. The nonresponder had no bloodwork. The longer author described libido rising around weeks three to four then falling, despite feeling leaner and stronger. That author reported substantial hormone suppression; a separate user described sluggish mood. Reddit r/sarmssourcetalk Personal report
  • The 'dry' reputation has exceptions. Water in arms and midsection appears in a late-gain log. Reports calling LGD cleaner than 'wet' orals describe a look, not a body-composition measurement or safety advantage. Reddit r/sarmssourcetalk Community
  • Stack gains cannot be assigned to LGD alone. MK-677 appears for appetite/recovery; RAD-140, Ostarine, S-4, YK-11 and GW-501516 occur in other stack talk. The longer author added MK-677 alongside injury care. Adding agents obscures benefit and adverse-effect attribution. Personal report Community
  • Support supplements are not a shield. Fish oil and liver-support products appear in stack discussions alongside warnings about heavy alcohol and other liver-stressing orals. Adding 'support' does not establish protection; the brief adverse log included multiple such products. Community Personal report
  • More milligrams do not settle nonresponse. Comments argue weak response versus incorrect product identity. Capsules, tablets and liquids bring different counting/error questions, and seller assurances cannot identify a consumed bottle. Neither no response nor a dramatic pump proves authenticity. Reddit r/sarmssourcetalk Community

Open in the directory ↗All STUDresearch topics →